Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. The distinguished honour comes as part of HM The King’s 2024 New Year Honours List, recognising the achievements and service of extraordinary people across the UK who have been recommended by the Prime Minister based on an independent assessment process.
The appointment reflects Andrew’s life-long passion for harnessing the power of innovative technologies to discover and develop high-quality medicines to benefit patients. This recognition follows multiple previous awards and prestigious honours recently received by both Andrew and Exscientia, the AI-driven precision medicine company he leads.
After publishing pioneering scientific papers on how machine learning and generative algorithms could be used to design novel drug leads, Andrew founded Exscientia in 2012 to create and develop the best possible drugs in the fastest and most effective manner. As the company’s CEO, Andrew led the group who discovered the first AI-designed drugs to enter human clinical trials. Today, he heads a global team of around 450 scientists and technology experts based in Oxford, UK, and globally. Prior to Exscientia, Andrew held the Chairs of Medicinal Informatics and Translational Biology at the University of Dundee and spent a decade at Pfizer Inc. leading various informatics groups. He received his doctorate in biophysics from the University of Oxford and his LLD from the University of Dundee where he also holds an Honorary Chair.
For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA for Best Digital Health Solution in late 2022, as well as the Prix Galien UK in the same category in May 2023. Also in May this year, Andrew was elected for life to two of the UK’s national academies in recognition of “exceptional contributions to science”, as Fellow of the Royal Society, the world’s oldest independent academic scientific body, and as Fellow of the Academy of Medical Sciences. In September, Andrew was featured on the inaugural TIME 100 AI list of most influential people in AI, while most recently, in November 2023, Exscientia was named to the inaugural Fortune 50 AI Innovators list.
“I’m truly humbled by this extraordinary recognition of the work of my outstanding team that I am privileged to lead,” said Andrew. “Our goal at Exscientia of utilising advanced technology to accelerate the design of new drugs, an idea that originated during my doctorate, has gained substantial momentum in changing the way future therapies may be created, evaluated and brought to patients in need of fast, effective and affordable treatment. Based on our progress so far, we believe all drugs will be designed and developed with AI and that this approach holds the key to transforming the trajectory of human health forever.”
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102661842/en/
Contact information
Investor Relations:
Sara Sherman
investors@exscientia.ai
Media & Photos:
Oliver Stohlmann
media@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g
Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation7.5.2025 19:55:00 EEST | Press release
Knowledge 2025 —Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today at ServiceNow’s annual customer and partner event, Knowledge 2025, announced that Apsen Farmacêutica, a Brazilian pharmaceutical manufacturer, has partnered with Rimini Street and ServiceNow to implement a next-generation vision of enterprise-wide workflow automation. This new vision will enable autonomy across the company to help respond faster to market changes, reduce information silos and improve operational efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507517040/en/ Rimini Street and ServiceNow Partner with Apsen Farmacêutica to Deliver a Next-Generation Vision of Enterprise-Wide Workflow Automation Apsen is prioritizing business needs above technology, leaning into a fl
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials7.5.2025 19:07:00 EEST | Press release
VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic obstructive pulmonary disease (COPD) provided Altesa BioSciences with compelling evidence to advance their lead drug candidate, vapendavir, into large scale, late-stage clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507489716/en/ Professor Sebastian Johnston https://www.prnewswire.com/news-releases/altesa-biosciences-details-positive-topline-vapendavir-results-from-phase-2-placebo-controlled-rhinovirus-challenge-study-in-copd-patients-302448650.html Rhinovirus infection is the cause of at least half of the acute respiratory deteriorations experienced by the millions of patients with chronic obstructive lung disease. “Before advancing vapendavir into clinical trials testing vapendavir on thousands of patients c
FlightSafety International Announces Major Expansion at Farnborough Airport7.5.2025 18:56:00 EEST | Press release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/ Rendering: arriving at FlightSafety International The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027. FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square met
Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK Matrix TM for In-App Protection by QKS Group7.5.2025 18:45:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/ Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The company has also been named an Ace Performer a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition—all evaluated over the last one-year period or since the previous SPARK Matrix assessment. The QKS Group SPARK Matrix™ provides competitive analysis & ranking of the leading In-App Protection vendors. For more information about Verimatrix, visit: https://www.verimatrix.com SPARK MatrixTM: In-App Protection, Q1 2025: https://qksgroup.com/market-research/spark-matrix-in-app-protection-q1-2025-8413 V
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom